On July 14, 2015 Kowa and Chugai reported that they have entered into license agreement of "peretinoin (development code: NIK-333)" for which Kowa is currently conducting clinical development for prevention of recurrence of hepatocellular carcinoma (Press release, Chugai, JUL 14, 2015, View Source [SID:1234506327]). Schedule your 30 min Free 1stOncology Demo! Under this agreement, Kowa will acquire the marketing authorization, and Chugai will have the exclusive marketing rights of the product supplied by Kowa in Japan. Under the terms of the agreements, Kowa will receive an upfront fee and milestone payments from Chugai.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Approximately 40,000 people are newly diagnosed with primary liver cancer in Japan each year, with approximately 30,000 deaths, and it is the fifth leading cause of death due to cancer. Hepatocellular carcinoma accounts for approximately 94% of primary liver cancer. The rate of recurrence of hepatocellular carcinoma after radical surgery is reported to be 30.1% in the first year, 62.3% in the third year, and 79.0% in the fifth year respectively.
Peretinoin is an oral acyclic retinoid with a vitamin A-like structure mainly targeting the retinoid nuclear receptor. It is the first drug in the world aiming at preventing the recurrence of hepatocellular carcinoma.
Through the introduction of peretinoin to the market, Kowa and Chugai expect to contribute to patients, their families, and medical professionals by fulfilling unmet medical needs and providing new treatment options.